Roman Butler Fullerton & Co. Has $261,000 Stock Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT)

Roman Butler Fullerton & Co. reduced its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 65.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,565 shares of the biotechnology company's stock after selling 10,466 shares during the period. Roman Butler Fullerton & Co.'s holdings in Corcept Therapeutics were worth $261,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Park Place Capital Corp acquired a new position in shares of Corcept Therapeutics in the 2nd quarter worth approximately $32,000. Atwood & Palmer Inc. bought a new position in shares of Corcept Therapeutics in the second quarter valued at $35,000. Kathleen S. Wright Associates Inc. acquired a new stake in shares of Corcept Therapeutics during the 3rd quarter valued at $36,000. Blue Trust Inc. boosted its stake in shares of Corcept Therapeutics by 125.4% during the 2nd quarter. Blue Trust Inc. now owns 3,526 shares of the biotechnology company's stock worth $115,000 after acquiring an additional 1,962 shares in the last quarter. Finally, GAMMA Investing LLC grew its holdings in shares of Corcept Therapeutics by 85.4% in the 3rd quarter. GAMMA Investing LLC now owns 2,490 shares of the biotechnology company's stock worth $115,000 after acquiring an additional 1,147 shares during the last quarter. 93.61% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

CORT has been the subject of several analyst reports. Piper Sandler upped their target price on Corcept Therapeutics from $38.00 to $67.00 and gave the company an "overweight" rating in a report on Wednesday, September 18th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $38.00 price objective on shares of Corcept Therapeutics in a research note on Tuesday, July 30th. HC Wainwright reissued a "buy" rating and issued a $80.00 target price on shares of Corcept Therapeutics in a research report on Thursday, October 31st. StockNews.com upgraded shares of Corcept Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Thursday, October 31st. Finally, Sandler O'Neill reiterated a "buy" rating on shares of Corcept Therapeutics in a research report on Friday, October 18th. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $65.25.

Insider Activity at Corcept Therapeutics

In other news, insider Gary Charles Robb sold 11,000 shares of the firm's stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $46.28, for a total transaction of $509,080.00. Following the completion of the sale, the insider now directly owns 22,772 shares of the company's stock, valued at $1,053,888.16. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other Corcept Therapeutics news, insider Gary Charles Robb sold 11,000 shares of the business's stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $46.28, for a total value of $509,080.00. Following the completion of the sale, the insider now directly owns 22,772 shares of the company's stock, valued at $1,053,888.16. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider William Guyer sold 10,000 shares of the firm's stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $35.30, for a total transaction of $353,000.00. Following the transaction, the insider now owns 6,039 shares in the company, valued at $213,176.70. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 24,101 shares of company stock valued at $972,817. Insiders own 20.50% of the company's stock.

Corcept Therapeutics Stock Up 4.2 %

Shares of NASDAQ CORT traded up $2.08 during mid-day trading on Tuesday, reaching $52.14. The company had a trading volume of 1,251,565 shares, compared to its average volume of 1,191,046. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.64 and a current ratio of 3.70. The company has a market capitalization of $5.46 billion, a price-to-earnings ratio of 39.98 and a beta of 0.45. The stock has a fifty day moving average of $42.70 and a two-hundred day moving average of $34.92. Corcept Therapeutics Incorporated has a 12-month low of $20.84 and a 12-month high of $52.35.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last released its earnings results on Wednesday, October 30th. The biotechnology company reported $0.41 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.27 by $0.14. Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. The company had revenue of $182.55 million during the quarter, compared to the consensus estimate of $171.97 million. During the same quarter in the prior year, the firm earned $0.28 EPS. The company's revenue was up 47.7% compared to the same quarter last year. As a group, equities research analysts expect that Corcept Therapeutics Incorporated will post 1.25 EPS for the current year.

Corcept Therapeutics Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.